Illumina to cut $100M in fiscal 2025 costs

Illumina to cut $100M in costs to cope with China ban
The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.
Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban
Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego-based Illumina is lowering its 2025 guidance to $4.
Diagnostic Kit Maker Illumina To Cut $100 Million In Costs, Lowers 2025 Profit Outlook Amid China Trade Restrictions
Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for high-single-digit growth by 2027.
Illumina aims to cut $100M in costs following China import ban
Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue from China, after the country banned the importation of its DN | Illumina also lowered its annual financial forecast,
Illumina to cut $100M in fiscal 2025 costs amid China ban
Illumina (ILMN) said it is instituting an incremental approximately $100M cost reduction program for fiscal 2025. The company added, “These
Illumina lowers outlook due to China sales ban, to cut $100 million in costs
Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban on imports of its genetic sequencing instruments. The company said it now expects 2025 adjusted profit of about $4.
JD Supra2h
The Illumina Ban and What It Means for Life Science Companies
Amid increasing economic tensions with the United States, China recently announced that it would ban Illumina, a U.S.-based company and the ...
Why Illumina, Inc. (ILMN) Is Plunging So Far In 2025
We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are ...
Illumina (ILMN) Gets a Buy from RBC Capital
In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...
China hits Illumina with import ban. What does that mean for the San Diego gene sequencer?
China imposed an import ban on Illumina’s gene sequencers in response to President Trump’s escalating tariffs and trade war ...
4ILMN : Illumina Unusual Options Activity
Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The ...